IE
NVET

Israel Englander’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Israel Englander’s Portfolio NVET Stock Details NVET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-19,000
Closed -$153K – 4120
2015
Q1 		$153K Buy
+19,000
New +$180K ﹤0.01% 3349

Other funds holding NVET

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return

Israel Englander's NVET Position: Q2 2015 in Review

Israel Englander sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q2 2015, closing a stake of 19,000 shares — an estimated $153K sold.

Israel Englander first reported a position in NVET in Q1 2015 and held it in 1 quarter. The position peaked at $153K in Q1 2015. 18 funds tracked by Wall St. Rank hold NVET as of Q2 2015.

  • Israel Englander reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q2 2015 after selling out during the quarter.
  • Israel Englander sold 19,000 Nexvet Biopharma plc Ordinary Shares shares in Q2 2015, an estimated $153K.
  • Israel Englander first reported a position in Nexvet Biopharma plc Ordinary Shares in Q1 2015 and held it in 1 quarter.
  • Israel Englander's Nexvet Biopharma plc Ordinary Shares position peaked at $153K in Q1 2015.
  • 18 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q2 2015.

Based on Millennium Management's 13F filing for Q2 2015, filed 14 Aug 2015.